Loading organizations...
Founded in 2003 by John Knopf, Jasbir Seehra, Tom Maniatis, Mark Ptashne, Wylie Vale, and Christoph Westphal, Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, that discovers protein therapeutics targeting the TGF-beta superfamily. The organization focuses its clinical research on patient populations suffering from serious and rare conditions such as pulmonary arterial hypertension, beta-thalassemia, and myelodysplastic syndromes. Before its acquisition, the enterprise scaled to over 300 employees, completed a 2013 public offering, generated over 92 million dollars in 2020 revenue, and established strategic commercial partnerships with pharmaceutical entities like Celgene and Bristol Myers Squibb. In November 2021, pharmaceutical giant Merck acquired the firm for over 11 billion dollars following its successful development of therapeutics. In March 2024, the FDA approved sotatercept, a blockbuster pulmonary arterial hypertension drug originally discovered and developed by the company.
Acceleron Pharma has raised $71.0M across 3 funding rounds.
Acceleron Pharma has raised $71.0M in total across 3 funding rounds.
Acceleron Pharma is a biopharmaceutical company, not a general technology company, focused on developing novel therapeutics that target the TGF-β superfamily of proteins to treat diseases involving bone, muscle, fat, vasculature, and blood cell regulation[1][3][4]. It builds drugs like sotatercept and luspatercept, which act as activin receptor antagonists or ligands to address unmet needs in rare blood disorders, pulmonary arterial hypertension, neuromuscular diseases, and cancer-related conditions such as bone and muscle loss[1][2][4]. The company serves patients with myelodysplastic syndromes (MDS), beta-thalassemia, pulmonary arterial hypertension, and metabolic/musculoskeletal disorders, solving problems like anemia, muscle wasting, and tissue degeneration through proprietary agonists and antagonists of growth factors[1][3]. Growth momentum includes first approvals like luspatercept in 2019, ongoing Phase 3 trials for sotatercept as of 2023, and an IPO in 2013 that advanced multiple Phase 2 programs[2][4].
Founded in June 2003 in Cambridge, Massachusetts (initially as Phoenix Pharma), Acceleron emerged from breakthroughs in growth and differentiation factors by academic scientists including Jasbir Seehra, Tom Maniatis, Mark Ptashne, Wylie Vale, and advisor Joan Massague, with business leaders John Knopf and Christoph Westphal (of Polaris Venture Partners) as key figures—Westphal served as founding CEO[3][4]. The idea stemmed from research on TGF-β superfamily proteins regulating cell growth, repair, and survival in tissues like muscle, bone, and blood vessels, targeting metabolic disorders (e.g., obesity, diabetes, osteoporosis) and muscle-wasting conditions[1][4]. Early traction came swiftly: the first clinical trial launched in June 2006 for ACE-011 (later sotatercept), a fusion protein for cancer-related bone loss, building on lab work from founders and consultants; by its 2013 IPO, three candidates (sotatercept, luspatercept, dalantercept) were in 12 Phase 2 trials[4].
Acceleron rides the wave of precision biologics targeting cytokine and growth factor pathways, amplified by advances in protein engineering and gene regulation insights from the Human Genome Project era[3][4]. Timing aligns with rising demand for orphan drug therapies amid aging populations and rare disease awareness, bolstered by FDA incentives for breakthroughs like luspatercept's 2019 approval—the first new MDS anemia treatment in decades[2][4]. Market forces favoring it include explosive growth in TGF-β modulators for fibrosis, cancer, and hematology (e.g., partnerships implied by trial progress), plus biotech hubs like Cambridge fostering talent and capital[1][3]. It influences the ecosystem by validating activin signaling as a hub for muscle/bone therapeutics, inspiring follow-ons in neuromuscular atrophy and metabolic syndromes while contributing to MassBio's innovation cluster[3].
Acceleron is poised for expansion via Phase 3 readouts for sotatercept in pulmonary hypertension and potential labels beyond MDS/thalassemia, leveraging its TGF-β platform amid surging demand for muscle-wasting and rare anemia solutions[2][4]. Trends like AI-driven protein design and combo therapies with immunotherapies will accelerate its pipeline, including preclinical assets for spinal muscular atrophy[2]. Its influence may evolve through acquisitions or partnerships, cementing leadership in growth factor biology as biotech shifts toward tissue repair modalities—echoing its founding mission to transform unmet needs in musculoskeletal and vascular diseases into approved realities[1][3][4].
Acceleron Pharma has raised $71.0M across 3 funding rounds. Most recently, it raised $10.0M Series U in June 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2010 | $10M Series U | — | 5AM Ventures, Abingworth, Advanced Technology Ventures, Bluebird Ventures, Flare Capital Partners, InterWest, OrbiMed, Polaris Partners, Venrock, Wildcat Ventures | Announced |
| Sep 1, 2007 | $31M Series C | — | 5AM Ventures, Abingworth, Flare Capital Partners, InterWest, OrbiMed, Polaris Partners, Venrock, Wildcat Ventures | Announced |
| Aug 1, 2006 | $30M Series B | — | 5AM Ventures, Abingworth, Advanced Technology Ventures, Bluebird Ventures, Flare Capital Partners, InterWest, OrbiMed, Polaris Partners, Venrock, Wildcat Ventures | Announced |
Acceleron Pharma has raised $71.0M in total across 3 funding rounds.
Acceleron Pharma's investors include 5AM Ventures, Abingworth, Advanced Technology Ventures, Bluebird Ventures, Flare Capital Partners, InterWest, OrbiMed, Polaris Partners, Venrock, Wildcat Ventures.
